EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy

Hao Wang, Encheng Liu, Mei Wu, Haijun Gao, Bing Lv, Guang Chen, Xunjin Zeng

Journal of Hepatocellular Carcinoma · 2026-02 · Volume 13 · 1-17

DOI: 10.2147/jhc.s570962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-02. Verfasst von Hao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Tianjin First Central Hospital, Tianjin, 300384, People's Republic of China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To develop a nomogram based on clinical characteristics for predicting post-transplant tumor recurrence in hepatocellular carcinoma (HCC) patients beyond the Milan criteria who received transarterial chemoembolization (TACE) bridging therapy.

Methods

A retrospective analysis included 73 such patients (29 conventional TACE [cTACE], 44 drug-eluting bead TACE [DEB-TACE]) who underwent liver transplantation at our institution between January 2013 and January 2020, with follow-up until January 2024 (mean: 33.2 ± 6.5 months). Clinical/pathological features were analyzed via univariate and multivariate Cox regression to identify recurrence-related factors, and a nomogram was constructed. Bootstrap validation (B=20) and receiver operating characteristic (ROC) curves (AUC) evaluated its performance.

Results

The 1-, 2-, 3-year cumulative recurrence rates were 17.8%, 23.3%, 24.7% (median recurrence time: 6 months). cTACE group rates (20.7%, 27.6%, 31.0%) were higher than DEB-TACE (15.9%, 20.5%, 20.5%; P=0.034). Independent risk factors: bridging therapy type (HR=2.402, P=0.034), microvascular invasion (HR=3.445, P=0.001), tumor necrosis rate (HR=26.664, P=0.002), pre-TACE AFP (HR=2.750, P=0.004). The nomogram's AUC for 1-, 2-, 3-year recurrence was 0.740, 0.764, 0.886, with good calibration via bootstrap.

Conclusion

A nomogram based on clinical characteristics accurately predicts post-transplant recurrence in HCC patients beyond the Milan criteria with TACE bridging therapy, providing guidance for optimizing donor allocation.

Schlagwörter

Stichwörter der Autor:innen

drug-eluting beadshepatocellular carcinomaliver transplantationtumor recurrence

Autor:innen und Institutionen

  • Department of Radiology, Tianjin First Central Hospital, Tianjin, 300384, People's Republic of China.

Zitieren

APA

Wang, H., Liu, E., Wu, M., Gao, H., Lv, B., Chen, G., & Zeng, X. (2026). Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy. Journal of Hepatocellular Carcinoma, Volume 13, 1-17. https://doi.org/10.2147/jhc.s570962

Vancouver

Wang H, Liu E, Wu M, Gao H, Lv B, Chen G, et al. Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-17. doi:10.2147/jhc.s570962

BibTeX
@article{Wang2026,
  author = {Wang, Hao and Liu, Encheng and Wu, Mei and Gao, Haijun and Lv, Bing and Chen, Guang and Zeng, Xunjin},
  title = {Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--17},
  doi = {10.2147/jhc.s570962}
}
Kostenlos starten →